卡泊芬净治疗恶性血液病合并IPA感染临床分析  

CLINICAL ANALYSIS OF CASPOFUNGIN IN TREATMENT OF HEMATOLOGICAL MALIGNANCIES COMBINED INVASIVE PULMONARY ASPERGILLOSIS INFECTION

作　　者：梁莉[1] 申徐良[1] 张梅香[1] 张国香[1] 魏武[1] 

机构地区：[1]长治医学院附属和平医院血液科,山西长治046000

出　　处：《承德医学院学报》2014年第1期26-28,共3页Journal of Chengde Medical University

摘　　要：目的:评估卡泊芬净治疗恶性血液病合并侵袭性肺曲霉菌(IPA)感染的临床疗效和安全性。方法:2008年1月-2012年12月恶性血液病合并IPA感染患者49例,所有患者均经CT检查和GM试验临床诊断;采用注射用醋酸卡泊芬净进行治疗,根据临床疗效标准,评价卡泊芬净治疗的疗效和安全性。结果:49例患者的治疗总有效率为91.84%(45/49)。卡泊芬净治疗过程中9例发生不良反应,不良反应发生率为18.37%。结论:卡泊芬净有很好的抗真菌活性,是治疗恶性血液病合并肺曲霉菌感染安全有效的药物。Objective：To evaluate the clinical efficacy and safety of caspofungin in treatment of hematological malignanciescombinedinvasivepulmonaryaspergillosis（IPA）infection.Methods：49hematologicalmalignanciescombined IPA infection patients （2008.1-2012.12） that were diagnosed by CT and galactomannan test were treated with caspofungin. The clinical efficacy and safety of caspofungin were evaluated according to clinical curative effect standard.Results：The total effective rate of 49 patients was 91.84%（45/49） after caspofungin treatment;and the incidence of drug related adverse events was 18.37%（9/49）.Conclusions：Caspofungin has good antifungal activity, and it is a safe and effective drug for treating hematological malignancies combinedIPAinfection.

关 键 词：卡泊芬净 恶性血液病 侵袭性肺曲霉菌病 感染 

分 类 号：R978.1[医药卫生—药品]